Article

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer

2023-05-16

Abstract excerpt

HER2 is a member of the growth factor receptor family. It is very weakly expressed in the few epithelial cells in normal tissue. The HER2 gene and protein are overexpressed in many solid tumors. Thus, there are many advantages of targeting HER2 in tumor therapy. Tumor relapse can be prevented by chimeric antigen receptor (CAR) T-cell therapy. The efficacy of CAR-T-cell therapy against tumors can be improved by add...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95e37890-332f-5efe-b067-1144784e44d4
DOI: 10.21203/rs.3.rs-2920088/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerDOI 10.21203/rs.3.rs-2920088/v1Read

Humanized CAR T cells targeting p95HER2Semantic proximity Read

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacySemantic proximity Read

Generation of Murine Carcinoma Models with Functional Heterologous HER1 and/or HER2 Receptors for In Vivo Study of Specific TherapiesSemantic proximity Read

Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T CellsSemantic proximity Read

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read

The Evolving Landscape of HER2 Targeting in Breast Cancer.Semantic proximity Read

Targeting the function of the HER2 oncogene in human cancer therapeuticsSemantic proximity Read

The human epidermal growth factor receptor 2 (HER2)Semantic proximity Read

Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library ApproachSemantic proximity Read

Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin.Semantic proximity Read

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine TargetsSemantic proximity Read

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapiesSemantic proximity Read